Semaglutide, the baseline everything else gets measured against

Where the GLP-1 story starts, and what the headline numbers leave out.

What it is

Semaglutide is a GLP-1 receptor agonist, a long-acting copy of a gut hormone your body releases after eating. It is approved for type 2 diabetes and for weight management, with the largest trial record of any peptide in this space.

How it works

It slows gastric emptying, prompts insulin release when blood sugar is high, and acts on appetite centres in the brain. The practical result is feeling full sooner and staying full longer, with less mental chatter about food between meals.

What people notice

Smaller portions without effort, in the first two or three weeks. Alcohol interest often drops too, which surprises people. Weight change follows over months, not weeks.

What to watch for

Nausea, reflux, and constipation head the list, mostly during dose increases. Published averages hide a wide spread: the trial figure is a middle point, with plenty of people well above and below it. Muscle loss is the quiet cost, and protein plus resistance work is the counterweight.

One thing to remember

Track waist measurement alongside weight. The two move at different speeds and the tape often tells the better story.